Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
ZS Pharma
July 20, 2017
Looking for value in the deal sweet spot
August 23, 2016
Who’s next after Medivation?
July 21, 2016
For the real Relypsa puzzle look beyond the takeover
May 27, 2016
Astra’s reckless $2.7bn deal hits the regulatory buffers
March 23, 2016
Brilinta and Pascal Soriot lose yet more lustre
December 22, 2015
Happy Christmas for Actelion, but what about the new year?
November 09, 2015
Forehead slaps in order for Astra as data dwarf $2.7bn deal
November 06, 2015
AstraZeneca pips Actelion to ZS Pharma
October 23, 2015
Up is down for Relypsa and Merrimack
September 11, 2015
Hyperkalaemia comes into play for Actelion
January 15, 2015
JPM 2015 – Relypsa awaits lift-off
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
February 10, 2021
2020 wins top of the froths for biotech stocks
October 04, 2018
Biotech flotations remain in high demand
February 04, 2021
Glaxo’s growth problem
January 27, 2021
Go or no go? Oncology decisions ahead for the FDA
February 05, 2021
Pfizer reveals its PD-1 secret
